[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f2i6u1x8dd8jzb":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":25,"specialties":31,"cover":11},917,"e4hdgvp58i3nwpa1jsuwa3f1","cytochrome-p450-3a5-inhibitors","Cytochrome P450 3A5 Inhibitors",null,"CYP3A5 is a cytochrome P450 monooxygenase that inserts one atom of molecular oxygen into its substrates - steroid hormones and vitamins - using two electrons supplied by NADPH through cytochrome P450 reductase. Drugs in this class reduce that catalytic activity, so a co-administered drug cleared by CYP3A5 is eliminated more slowly and accumulates. FDA grades the consequence by how far a sensitive index substrate's exposure rises, calling an inhibitor strong at a >=5-fold increase in AUC and moderate at >=2- to \u003C5-fold. A drug belongs here because its recorded effect on CYP3A5 is inhibition, not induction.",[14,20],{"source":15,"licence":16,"source_url":17,"harvested_by":18,"retrieved_at":19},"RxClass (NLM)","US public domain","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002Fclass\u002FbyId.json?classId=N0000190115","load-reference-corpus.cjs","2026-09-13",{"source":21,"licence":22,"source_url":23,"harvested_by":18,"retrieved_at":24},"UniProt Knowledgebase entry P20815 (Cytochrome P450 3A5)","CC BY 4.0 (UniProt Consortium)","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP20815.json","2026-09-16",[26],{"id":27,"documentId":28,"slug":29,"name":30,"active_ingredient":30,"dosage_form":11,"administration_route":11},1581,"qbx84ldo1uoc46l9sj7m129b","ketoconazole","Ketoconazole",[]]